Fatostatin induces ferroptosis through inhibition of the AKT/mTORC1/GPX4 signaling pathway in glioblastoma

[1]  Yuan Xie,et al.  HIF-α activation by the prolyl hydroxylase inhibitor roxadustat suppresses chemoresistant glioblastoma growth by inducing ferroptosis , 2022, Cell Death & Disease.

[2]  E. Bongarzone,et al.  Tumor-targeting cell-penetrating peptide, p28, for glioblastoma imaging and therapy , 2022, Frontiers in Oncology.

[3]  Yang Xu,et al.  TMBIM1 promotes proliferation and attenuates apoptosis in glioblastoma cells by targeting the p38 MAPK signalling pathway , 2022, Translational oncology.

[4]  Marek J. Łos,et al.  Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma , 2022, International journal of molecular sciences.

[5]  Michael R Hamblin,et al.  Crosstalk between ferroptosis and the epithelial-mesenchymal transition: Implications for inflammation and cancer therapy. , 2022, Cytokine & growth factor reviews.

[6]  Shengbiao Li,et al.  RSL3 Drives Ferroptosis through NF-κB Pathway Activation and GPX4 Depletion in Glioblastoma , 2021, Oxidative medicine and cellular longevity.

[7]  N. Bernardes,et al.  p28-functionalized PLGA nanoparticles loaded with gefitinib reduce tumor burden and metastases formation on lung cancer. , 2021, Journal of controlled release : official journal of the Controlled Release Society.

[8]  Zhiming Liu,et al.  Fatostatin reverses progesterone resistance by inhibiting the SREBP1-NF-κB pathway in endometrial carcinoma , 2021, Cell Death & Disease.

[9]  Junjie Chen,et al.  mTORC1 couples cyst(e)ine availability with GPX4 protein synthesis and ferroptosis regulation , 2021, Nature Communications.

[10]  M. Conrad,et al.  The Metabolic Underpinnings of Ferroptosis. , 2020, Cell metabolism.

[11]  H. Friedman,et al.  Management of glioblastoma: State of the art and future directions. , 2020, CA: a cancer journal for clinicians.

[12]  P. Shang,et al.  Ferroptosis, a novel pharmacological mechanism of anti-cancer drugs. , 2020, Cancer letters.

[13]  Wei-Hwa Lee,et al.  Disruption of Cancer Metabolic SREBP1/miR-142-5p Suppresses Epithelial–Mesenchymal Transition and Stemness in Esophageal Carcinoma , 2019, Cells.

[14]  K. Yadav,et al.  Understanding the biology and advent of physics of cancer with perspicacity in current treatment therapy. , 2019, Life sciences.

[15]  T. Maekawa,et al.  Chlorotoxin modified morusin-PLGA nanoparticles for targeted glioblastoma therapy. , 2019, Journal of materials chemistry. B.

[16]  M. Soukhtanloo,et al.  Role of AKT and mTOR Signaling Pathways in the Induction of Epithelial-Mesenchymal Transition (EMT) Process. , 2019, Biochimie.

[17]  Yihan Yang,et al.  NKCC1 promotes EMT‐like process in GBM via RhoA and Rac1 signaling pathways , 2018, Journal of cellular physiology.

[18]  J. Frasor,et al.  Fatostatin induces pro- and anti-apoptotic lipid accumulation in breast cancer , 2018, Oncogenesis.

[19]  Zhiming Liu,et al.  Fatostatin suppresses growth and enhances apoptosis by blocking SREBP-regulated metabolic pathways in endometrial carcinoma. , 2018, Oncology reports.

[20]  A. Elia,et al.  New Directions in the Treatment of Glioblastoma , 2018, Seminars in Neurology.

[21]  S. Lipton,et al.  Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 , 2018, Cell Death & Differentiation.

[22]  S. Lipton,et al.  Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 , 2018, Cell Death & Differentiation.

[23]  Leland S. Hu,et al.  Is the blood–brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data , 2018, Neuro-oncology.

[24]  Fei-Fei An,et al.  Strategies for Preparing Albumin-based Nanoparticles for Multifunctional Bioimaging and Drug Delivery , 2017, Theranostics.

[25]  William A Weiss,et al.  Inhibiting 4EBP1 in Glioblastoma , 2017, Clinical Cancer Research.

[26]  K. Williams,et al.  Fatostatin Inhibits Cancer Cell Proliferation by Affecting Mitotic Microtubule Spindle Assembly and Cell Division* , 2016, The Journal of Biological Chemistry.

[27]  Junhui Liu,et al.  Systemic delivery to central nervous system by engineered PLGA nanoparticles. , 2016, American journal of translational research.

[28]  M. Giorgio,et al.  A novel neuroferritinopathy mouse model (FTL 498InsTC) shows progressive brain iron dysregulation, morphological signs of early neurodegeneration and motor coordination deficits , 2015, Neurobiology of Disease.

[29]  Yunhui Liu,et al.  Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine-γ-lyase function. , 2015, Oncology reports.

[30]  D Andrews,et al.  Essential versus accessory aspects of cell death: recommendations of the NCCD 2015 , 2014, Cell Death and Differentiation.

[31]  N. Bernardes,et al.  Bacterial proteins and peptides in cancer therapy , 2014, Bioengineered.

[32]  Xiangyan Li,et al.  Fatostatin Displays High Antitumor Activity in Prostate Cancer by Blocking SREBP-Regulated Metabolic Pathways and Androgen Receptor Signaling , 2014, Molecular Cancer Therapeutics.

[33]  Matthew E. Welsch,et al.  Regulation of Ferroptotic Cancer Cell Death by GPX4 , 2014, Cell.

[34]  V. Préat,et al.  PLGA-based nanoparticles: an overview of biomedical applications. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[35]  D. Majumdar,et al.  A peptide fragment of azurin induces a p53-mediated cell cycle arrest in human breast cancer cells , 2009, Molecular Cancer Therapeutics.

[36]  M. Magzoub,et al.  Cancer targeting peptides , 2019, Cellular and Molecular Life Sciences.

[37]  A. Walch,et al.  ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. , 2017, Nature chemical biology.

[38]  Sudesh Kumar Yadav,et al.  Biodegradable polymeric nanoparticles based drug delivery systems. , 2010, Colloids and surfaces. B, Biointerfaces.